Masimo Corporation (MASI) Stock Analysis
Healthcare · Medical Devices
Sell if holding. At $179.95, A.R:R is negative (-1.0) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Masimo SET® platform and rainbow SET® platform; Concentration risk — Supplier: sole or limited source suppliers.
Masimo develops and sells noninvasive patient monitoring technologies including Masimo SET pulse oximetry, rainbow Pulse CO-Oximetry, and hospital automation/connectivity solutions to hospitals and care providers globally. The company sold its non-healthcare consumer business... Read more
Sell if holding. At $179.95, A.R:R is negative (-1.0) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Masimo SET® platform and rainbow SET® platform; Concentration risk — Supplier: sole or limited source suppliers. Chart setup: No clear chart pattern; technical signals are mixed. Score 6.0/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 52d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated 2026-06-14Recent Developments — Masimo Corporation
Latest news
- NEWS Sirius XM Holdings Will Replace Masimo Corp. In The S&P MidCap 400 Effective Prior To The Opening Of Trading On Thursday — benzinga Jun 8, 2026 negative
- NEWS Masimo Stockholders Approve Merger Agreement With Danaher, Mobius Merger Sub — benzinga May 4, 2026 positive
- NEWS Masimo's Appeal Rejection, M5 Chip Push, China Smartphone Growth, Foldable iPhone: This Week In Appleverse — benzinga Apr 19, 2026 negative
- NEWS Apple Scores Key Win As Trade Commission Rejects Masimo's Bid To Reinstate Apple Watch Import Ban — benzinga Apr 18, 2026 negative
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductMasimo SET® platform and rainbow SET® platform10-K Item 1A: 'We currently derive a significant portion of our revenue from our Masimo SET® platform, Masimo rainbow SET® platform and related products'
- HIGHSuppliersole or limited source suppliers10-K Item 1A: 'If we are unable to obtain key materials and components from sole or limited source suppliers, we will not be able to deliver our products to customers'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $179.95, A.R:R is negative (-1.0) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Masimo SET® platform and rainbow SET® platform; Concentration risk — Supplier: sole or limited source suppliers. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $179.23. Score 6.0/10, moderate confidence.
Take-profit target: $176.39 (-2.0% upside). Prior stop was $179.23. Stop-loss: $179.23.
Concentration risk — Product: Masimo SET® platform and rainbow SET® platform; Concentration risk — Supplier: sole or limited source suppliers; Analyst target reached - limited upside remaining.
Masimo Corporation trades at a P/E of 44.4 (forward 26.8). TrendMatrix value score: 4.7/10. Verdict: Sell.
15 analysts cover MASI with a consensus score of 3.5/5. Average price target: $180.
What does Masimo Corporation do?Masimo develops and sells noninvasive patient monitoring technologies including Masimo SET pulse oximetry, rainbow...
Masimo develops and sells noninvasive patient monitoring technologies including Masimo SET pulse oximetry, rainbow Pulse CO-Oximetry, and hospital automation/connectivity solutions to hospitals and care providers globally. The company sold its non-healthcare consumer business (Sound United) to Samsung/Harman in September 2025 and entered a pending merger agreement with Danaher Corporation at $180/share announced February 16, 2026.